Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19000756 | 0.93 | KDM4E (0.42) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL9068739 | 0.92 | APEX1 (0.36) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL9171615 | 0.89 | ALDH1A1 (0.39) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL9347144 | 0.86 | APEX1 (0.40) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL20696111 | 0.85 | APEX1 (0.39) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL29349873 | 0.85 | CA1 (0.41) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL9347011 | 0.85 | CA1 (0.41) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL26607 | 0.85 | CA1 (0.41) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL19020197 | 0.84 | APEX1 (0.39) | APEX1CA1CA2CA9CYP2C19 | |
| SCHEMBL30267754 | 0.84 | APEX1 (0.39) | APEX1CA1CA2CA9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0374761-B1 | PROCESS FOR THE PREPARATION OF ORGANOPHOSPHORUS COMPOUNDS OF 4,4-DIORGANOMAGNESIUM BIPHENYL, AND USE OF ORGANOPHOSPHORUS COMPOUNDS AS STABILIZERS FOR POLYMERS, PARTICULARLY POLYOLEFINE MOULDING COMPOSITIONS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-05 | — | — | EP | claimed |
| CN-114057548-B | Method for recovering 2, 4-di-tert-butylphenol from concentrated mother liquor of antioxidant 168 | 陕西艾科莱特新材料有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116947606-A | Method for recovering 2, 4-di-tert-butylphenol from antioxidant 168 mother liquor | 营口风光新材料股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-114057548-A | Method for recovering 2, 4-di-tert-butylphenol from antioxidant 168 concentrated mother liquor | 陕西艾科莱特新材料有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-108070001-B | Bisphosphites having a 2, 4-tert-butylphenyl unit and their use as ligands in hydroformylation | 赢创运营有限公司 | 2020-10-13 | — | — | CN | disclosed |
| US-10011619-B2 | Process for reducing the chlorine content of organotetraphosphites | EVONIK DEGUSSA GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| US-20180127444-A1 | BISPHOSPHITES HAVING 2,4-TERT-BUTYLPHENYL UNITS AND USE THEREOF AS LIGANDS IN HYDROFORMYLATION | EVONIK DEGUSSA GMBH (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9908910-B2 | Bidentate diphosphoramidites with a piperazine group as ligands for hydroformylation | EVONIK DEGUSSA GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-9908910-B2 | Bidentate diphosphoramidites with a piperazine group as ligands for hydroformylation | EVONIK DEGUSSA GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-9896404-B2 | Bidentate diphosphoramidites with a homopiperazine group as ligands for hydroformylation | EVONIK DEGUSSA GMBH (DE) | 2018-02-20 | — | — | US | disclosed |
| US-5210260-A | PROCESS FOR OBTAINING BIS(2,4-DI-TERT-BUTYLPHENYL) HALOPHOSPHITES | HOECHST AG (DE) | 1993-05-11 | — | — | US | disclosed |
| US-5109043-A | Reacting 4,4'-dihalobiphenyl with suspension of finely divided magnesium to form grignard reagent | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-04-28 | — | — | US | disclosed |
| US-5109043-A | Reacting 4,4'-dihalobiphenyl with suspension of finely divided magnesium to form grignard reagent | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-04-28 | — | — | US | disclosed |
| US-5061818-A | Fluorination with metal or ammonium fluoride in presence of pyridine halide salt | ETHYL CORPORATION (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0374761-A1 | Process for the preparation of organophosphorus compounds of 4,4-diorganomagnesium biphenyl, and use of organophosphorus compounds as stabilizers for polymers, particularly polyolefine moulding compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-06-27 | — | — | EP | disclosed |
| EP-0358985-A1 | Method of transhalogenating a halophosphorus compound with fluoride | ETHYL CORPORATION (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0312915-A2 | Process for making cyclic aryl chlorophosphites | ETHYL CORPORATION (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0312790-A2 | Process for transhalogenating a halophosphorus compound with fluoride | ETHYL CORPORATION (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4739000-A | FOR ORGANIC POLYMERS | ETHYL CORPORATION (US) | 1988-04-19 | — | — | US | disclosed |
| US-4724247-A | NONHYDROLYZING; POLYMER STABILIZERS | ETHYL CORPORATION (US) | 1988-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011619-B2 | Process for reducing the chlorine content of organotetraphosphites | DCPS, DDT, TET2 | APEX1 2071/4885CA1 665/4885CA2 356/4885 |
| US-20180127444-A1 | BISPHOSPHITES HAVING 2,4-TERT-BUTYLPHENYL UNITS AND USE THEREOF AS LIGANDS IN HYDROFORMYLATION | BPGM, NUDT1, PHPT1 | APEX1 354/4885CA1 1923/4885CA2 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.